Nordea Investment Management AB Trims Stock Position in Biogen Inc. $BIIB

Key Points

• Nordea Investment Management AB reduced its stake in Biogen (NASDAQ:BIIB) by 89.4% in Q4, selling 118,561 shares and leaving 14,022 shares valued at about $2.46 million.
• Other large institutions added or enlarged positions—Norges Bank established a new ~$284.4M stake and firms like Orion, Caisse de dépôt, AQR and Arrowstreet made sizable purchases—resulting in institutional ownership of 87.93%.
• Analysts hold a mixed view with a consensus Hold rating and $205.31 price target; Biogen recently beat quarterly EPS expectations ($1.99 vs. $1.61) and set FY2026 guidance of 15.25–16.25 EPS.

Nordea Investment Management AB trimmed its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 89.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,022 shares of the biotechnology company's stock after selling 118,561 shares during the period. Nordea Investment Management AB's holdings in Biogen were worth $2,458,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Biogen in the second quarter worth approximately $284,358,000. Orion Porfolio Solutions LLC grew its holdings in Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company's stock valued at $64,965,000 after purchasing an additional 509,809 shares during the period. Caisse de depot et placement du Quebec increased its position in Biogen by 718.2% during the third quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company's stock worth $79,741,000 after purchasing an additional 499,676 shares during the last quarter. AQR Capital Management LLC raised its stake in Biogen by 30.7% during the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company's stock worth $248,809,000 after purchasing an additional 418,776 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its stake in Biogen by 190.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company's stock worth $78,415,000 after purchasing an additional 409,591 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on BIIB shares. Oppenheimer boosted their price objective on shares of Biogen from $205.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, January 30th. Barclays assumed coverage on Biogen in a report on Thursday, February 19th. They issued an "equal weight" rating and a $185.00 target price on the stock. Mizuho boosted their price target on Biogen from $207.00 to $236.00 and gave the company an "outperform" rating in a research report on Tuesday, February 10th. UBS Group began coverage on Biogen in a research note on Tuesday, January 6th. They set a "neutral" rating and a $185.00 price target for the company. Finally, Truist Financial raised their price objective on Biogen from $190.00 to $193.00 and gave the stock a "hold" rating in a report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $205.31.

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of the firm's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.18% of the company's stock.

Biogen Stock Performance

NASDAQ:BIIB opened at $183.84 on Friday. The firm's fifty day simple moving average is $185.36 and its 200 day simple moving average is $170.05. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41. The firm has a market capitalization of $26.98 billion, a price-to-earnings ratio of 20.87, a PEG ratio of 1.52 and a beta of 0.15.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm's quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts expect that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.